Zenosense, Inc. (ZENO) Developing Improved Antibio
Post# of 53
Posted On: 03/03/2015 4:50:53 PM
Zenosense, Inc. (ZENO) Developing Improved Antibiotic-Resistant Infection Detection Solution
Methicillin-resistant Staphylococcus aureus (MRSA) infections account for an estimated 23,000 deaths per year in the United States alone. While current diagnostic testing procedures can take up to three days, Zenosense, Inc. (OTCQB: ZENO), in concert with development partner Zenon Biosystem, is developing a new, low cost sensor platform that will help decrease diagnosis times and, potentially, save the lives of millions of patients around the world.
The company’s technology will depend on the presence of Volatile Organic Compounds (VOCs), which are emitted by MRSA infections long before other symptoms become visible, making earlier intervention a distinct possibility. The diagnostic tool is currently being developed in two unique forms, including a wearable device designed to be positioned directly on patients and medical staff, as well as a fixed device engineered to consistently monitor a specified area in which the potential for infection is present, such as a hospital room.
According to reports from the Center for Disease Control, while MSRA infections in the community are typically relatively minor, those in medical facilities commonly cause life-threatening bloodstream infections, pneumonia and surgical site infections. The contaminations are particularly dangerous because the presence of two subpopulations, of which only one may be resistant to antibiotic treatment, can seriously hamper the accuracy of existing detection methods. Through its unique VOC sensor, Zenosense is preparing to address the serious flaws present in current MSRA detection options.
Zenosense began its development program of an MRSA infection sensing device in December 2013. Phase I activity on the project includes substantial engineering work, as the company expects greater than 90% sensitivity for the detection of MRSA-specific VOCs in patients.
As antibiotic-resistant bacteria threatens to return us to the time when simple infections were often fatal, the early and accurate detection of these contagions is the only way to minimize health risks. With Zenosense continuing its development of a revolutionary VOC sensing MRSA diagnostic device, the company could be in position for massive demand from the global healthcare industry in the near future.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Methicillin-resistant Staphylococcus aureus (MRSA) infections account for an estimated 23,000 deaths per year in the United States alone. While current diagnostic testing procedures can take up to three days, Zenosense, Inc. (OTCQB: ZENO), in concert with development partner Zenon Biosystem, is developing a new, low cost sensor platform that will help decrease diagnosis times and, potentially, save the lives of millions of patients around the world.
The company’s technology will depend on the presence of Volatile Organic Compounds (VOCs), which are emitted by MRSA infections long before other symptoms become visible, making earlier intervention a distinct possibility. The diagnostic tool is currently being developed in two unique forms, including a wearable device designed to be positioned directly on patients and medical staff, as well as a fixed device engineered to consistently monitor a specified area in which the potential for infection is present, such as a hospital room.
According to reports from the Center for Disease Control, while MSRA infections in the community are typically relatively minor, those in medical facilities commonly cause life-threatening bloodstream infections, pneumonia and surgical site infections. The contaminations are particularly dangerous because the presence of two subpopulations, of which only one may be resistant to antibiotic treatment, can seriously hamper the accuracy of existing detection methods. Through its unique VOC sensor, Zenosense is preparing to address the serious flaws present in current MSRA detection options.
Zenosense began its development program of an MRSA infection sensing device in December 2013. Phase I activity on the project includes substantial engineering work, as the company expects greater than 90% sensitivity for the detection of MRSA-specific VOCs in patients.
As antibiotic-resistant bacteria threatens to return us to the time when simple infections were often fatal, the early and accurate detection of these contagions is the only way to minimize health risks. With Zenosense continuing its development of a revolutionary VOC sensing MRSA diagnostic device, the company could be in position for massive demand from the global healthcare industry in the near future.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)